Cold type haemolytic anaemia, also known as cold agglutinin disease, is a rare blood condition where your body’s immune system mistakenly attacks and destroys red blood cells when exposed to cold temperatures, causing a range of symptoms from mild tiredness to serious health complications.

Epidemiology

Cold type haemolytic anaemia is an extremely rare condition that affects very few people worldwide. Approximately one person in every million receives a diagnosis each year, making it one of the more uncommon blood disorders that doctors encounter in clinical practice^[1]. In the United States, estimates suggest that between 300 and 3,000 people are currently living with this condition at any given time, highlighting just how infrequent it truly is^[1].

The disease does not affect everyone equally. Cold agglutinin disease shows a clear pattern in who it affects most often. Women are more likely to develop this condition than men, particularly those between the ages of 40 and 80 years^[1]. The typical person diagnosed with this condition is usually in their mid to late 60s, suggesting that age plays an important role in who develops the disease^[1][3]. While the condition can technically occur at any age, seeing it in younger people, especially children, is unusual.

The disease follows distinct patterns depending on whether it is primary or secondary in nature. Primary cold agglutinin disease, which occurs without any obvious underlying cause, tends to be a chronic or long-lasting condition that mainly affects older adults, particularly after the fifth decade of life^[3]. In contrast, secondary cold agglutinin disease, which develops as a result of another health problem like an infection or cancer, can occur at different ages. When caused by infections, particularly in children and young adults, the condition is usually temporary and resolves once the infection clears^[3][4].

Causes

Cold type haemolytic anaemia develops when the body’s immune system malfunctions and begins attacking its own healthy red blood cells. The immune system normally produces proteins called antibodies to fight off harmful germs and protect the body from infections. However, in cold agglutinin disease, the immune system creates a special type of antibody called an autoantibody that mistakenly identifies red blood cells as dangerous invaders^[1].

The specific autoantibody involved in this condition is usually immunoglobulin M, or IgM for short. In approximately 90% of cases, IgM is the culprit behind the red blood cell destruction, though occasionally other antibody types may be involved^[3][4]. What makes this autoantibody unique is that it becomes activated by cold temperatures. When body tissues cool down to approximately 37 to 39 degrees Fahrenheit (3 to 4 degrees Celsius), these cold-reactive antibodies spring into action^[1][8].

The process of red blood cell destruction happens in stages. First, the cold autoantibodies attach themselves to red blood cells when they are exposed to cooler temperatures in parts of the body that are farther from the warm core, such as fingers, toes, and ears. Once marked by these antibodies, the red blood cells clump together, a process called agglutination^[1]. These clumped cells then activate another part of the immune system called complement, which leads to their destruction. Finally, immune cells called macrophages finish the job by removing and destroying these marked cells^[1][4].

Understanding why the body produces these harmful autoantibodies in the first place depends on whether the disease is primary or secondary. In primary cold agglutinin disease, which accounts for many cases, the condition is usually linked to a clonal lymphoproliferative disorder. This means that certain immune cells in the bone marrow, specifically B-cells, grow abnormally and produce the harmful IgM antibodies^[3][4]. The exact trigger for this abnormal cell growth remains unknown in most cases.

Secondary cold agglutinin disease has identifiable causes. Infections are a common trigger, particularly in younger people. Cold agglutinins develop in more than 60% of patients with infectious mononucleosis, though actual haemolytic anaemia from this infection is rare^[2]. Bacterial infections like Mycoplasma pneumoniae, which causes a type of pneumonia, are well-known triggers^[2][4]. Various viral infections can also spark the condition, including Epstein-Barr virus, cytomegalovirus, mumps, varicella, rubella, adenovirus, HIV, influenza, and hepatitis C^[2].

Beyond infections, several other conditions can cause secondary cold agglutinin disease. Blood cancers such as lymphoma, chronic lymphocytic leukaemia, Waldenström macroglobulinaemia, and myeloma are associated with this condition^[2]. Certain autoimmune diseases, particularly systemic sclerosis (scleroderma), can trigger cold agglutinin disease, with the severity of anaemia sometimes reflecting the activity of the underlying autoimmune condition^[2]. Even some medical treatments, such as certain medications used after organ transplants (tacrolimus and cyclosporine), have been linked to the development of this condition^[2].

Risk Factors

Several factors can increase a person’s likelihood of developing cold type haemolytic anaemia. Age stands out as a significant risk factor, with the condition being most common in people over 40 years old and particularly those in their 60s and 70s^[1][3]. Being female also appears to increase risk, as women develop the condition more frequently than men^[1].

Having certain underlying health conditions significantly raises the risk of developing secondary cold agglutinin disease. People with blood cancers are at higher risk, particularly those with B-cell disorders like lymphoma, chronic lymphocytic leukaemia, or Waldenström macroglobulinaemia^[2][3]. These cancers involve the same type of immune cells that produce the harmful autoantibodies responsible for red blood cell destruction.

Individuals with other autoimmune diseases face increased risk as well. Those living with systemic sclerosis, an autoimmune condition that causes skin and organ hardening, may develop cold agglutinin disease, and interestingly, the degree of anaemia may reflect how active their underlying autoimmune disease is^[2]. Having one autoimmune condition appears to make the body more prone to developing others.

Recent or current infections create temporary risk, especially in children and young adults. Mycoplasma pneumoniae infections are particularly associated with cold agglutinin development^[2][4]. Viral infections including infectious mononucleosis (caused by Epstein-Barr virus), cytomegalovirus, mumps, varicella (chickenpox), rubella, HIV, influenza, and hepatitis C can all trigger the condition^[2]. Less commonly, bacterial infections like Legionnaire’s disease, syphilis, and infections caused by Listeria or E. coli bacteria, as well as parasitic infections such as malaria and trypanosomiasis, may increase risk^[2].

People who have undergone organ transplantation and are taking specific immunosuppressive medications may be at increased risk. Drugs called calcineurin inhibitors, including tacrolimus and cyclosporine, have been associated with the development of cold agglutinin disease in some transplant recipients^[2]. These medications work by affecting certain immune cells but may inadvertently allow the development of cells that produce autoantibodies.

Symptoms

The symptoms of cold type haemolytic anaemia can vary greatly from person to person, ranging from barely noticeable to severe and debilitating. Many symptoms relate directly to having too few red blood cells, a condition called anaemia, while others result from poor blood circulation caused by clumped red blood cells^[1][5].

Fatigue is one of the most common complaints among people with this condition. This tiredness goes beyond normal exhaustion and can feel overwhelming, making it difficult to complete everyday activities. Along with fatigue, many people experience general weakness throughout their body, as their cells are not receiving enough oxygen to produce the energy needed for normal function^[1][5]. Dizziness is another frequent symptom, which may occur when standing up or during physical activity.

Breathing problems often develop as the body struggles with low red blood cell counts. People may notice shortness of breath, also called dyspnoea, especially during exertion or physical activity. The heart may try to compensate for the lack of oxygen-carrying red blood cells by beating faster, leading to tachycardia (a fast heartbeat) or heart palpitations^[1][5]. Some people experience chest pain, which should always be taken seriously and evaluated promptly by a healthcare provider.

The skin often provides visible clues to this condition. Many people develop pallor, which means their skin appears unusually pale or drained of colour^[1][5]. Another distinctive sign is a condition called jaundice, where the skin and the whites of the eyes take on a yellowish tint. This happens because as red blood cells break down, they release a substance called bilirubin, which builds up in the body and causes this yellow discolouration^[1][5]. The urine may also become dark brown in colour due to the presence of bilirubin or haemoglobin^[1][5].

What makes cold agglutinin disease unique are symptoms specifically triggered by cold exposure. A particularly characteristic symptom is painful fingers and toes that develop a purplish or bluish discolouration when exposed to cold temperatures, a condition known as acrocyanosis or Raynaud’s phenomenon^[3][5][4]. This can happen not just in freezing weather but sometimes even in mildly cool conditions. The ears and nose may also turn bluish or reddish when cold. Some people notice that their hands and feet feel unusually cold compared to the rest of their body^[5].

It is important to understand how acrocyanosis in cold agglutinin disease differs from classic Raynaud’s phenomenon. In typical Raynaud’s, which is caused by blood vessel spasms, affected areas go through a three-stage colour change: first turning white, then blue, and finally red as blood flow returns. In cold agglutinin disease, this specific pattern does not occur. Instead, the discolouration results from red blood cells clumping together in cooler parts of the body rather than from blood vessel constriction^[2].

The timing and severity of symptoms often depend on the season and climate. People with chronic cold agglutinin disease typically feel worse during colder months and may experience significant improvement during warmer seasons^[3]. Some individuals have such mild symptoms that they live with the condition for several years before realising anything is wrong and seeking medical attention^[1]. Others experience severe symptoms that require immediate medical care.

Additional symptoms can include headaches, sweating, muscle pain, digestive problems like nausea or vomiting, and back or leg pain^[1][5]. Some people may notice respiratory symptoms if their cold agglutinin disease developed following a Mycoplasma pneumoniae infection^[2]. In rare cases, particularly after prolonged cold exposure, people may pass dark-coloured urine containing haemoglobin, a condition called haemoglobinuria^[2].

In severe cases, cold agglutinin disease can lead to serious complications affecting the heart. The strain of chronic anaemia can contribute to heart failure, irregular heart rhythms (arrhythmias), or heart murmurs^[5]. People with this condition also have an increased risk of developing blood clots and strokes^[5]. These serious complications highlight why prompt recognition and proper management of the condition are so important.

Prevention

Preventing cold type haemolytic anaemia entirely is not always possible, particularly when it comes to primary disease where no clear trigger exists. However, people already diagnosed with the condition can take important steps to prevent symptoms and complications, especially those related to cold exposure.

The most fundamental preventive measure for people with cold agglutinin disease is avoiding cold temperatures whenever possible. This means staying indoors during cold weather, particularly on the coldest days of winter^[6][14]. When planning outdoor activities, checking the weather forecast, including wind chill factors, helps people make informed decisions about whether to go out and what precautions to take. Many people find it helpful to schedule outdoor errands during the warmest part of the day.

Proper clothing is essential for those who must venture outside in cold weather. Dressing in multiple loose layers is more effective than wearing one heavy garment, as air trapped between layers provides insulation^[15]. The outer layer should protect against wind, rain, and snow. The fabric choice matters too – synthetic materials help retain warmth even when they become damp, whereas cotton loses its insulating properties when wet^[15].

Protecting the head and face is particularly important because approximately 10% of body heat escapes through the head^[15]. Wearing a warm hat or hood when outdoors prevents this heat loss. A knit mask, balaclava, or even a simple scarf covering the lower face can protect against cold air. Some people find it helpful to wear a hat even indoors if their home or workplace feels chilly.

The hands and feet, which are especially vulnerable to cold-triggered symptoms in this condition, need special attention. Insulated, waterproof gloves are essential for outdoor activities^[15]. Some people may need to wear gloves even for brief cold exposures, such as reaching into a refrigerator or freezer^[6][14]. Water-resistant boots or shoes help keep feet warm and dry. Applying waterproofing spray to shoes provides additional protection^[15].

At home, maintaining a warm indoor environment helps prevent symptom flare-ups. Setting the thermostat to a comfortable temperature and using space heaters in particularly cold rooms can help. Some people find that avoiding cold foods and beverages reduces symptoms^[6][14]. For those who drive, installing a remote car starter allows the vehicle to warm up before entering it, avoiding exposure to the cold car interior.

For individuals at risk of developing secondary cold agglutinin disease, managing underlying conditions is crucial. People with autoimmune diseases should work closely with their healthcare providers to keep these conditions well-controlled. Those with infections that can trigger cold agglutinin disease should receive prompt and appropriate treatment. While this does not guarantee prevention of cold agglutinin disease, it may reduce risk or severity.

Pathophysiology

Understanding the pathophysiology of cold type haemolytic anaemia means looking at how normal body processes go wrong at the cellular and molecular level. The disease fundamentally disrupts the normal life cycle of red blood cells and involves complex interactions between antibodies, red blood cells, and the immune system’s complement pathway.

Under normal circumstances, red blood cells live for approximately 120 days before they naturally break down and are replaced by new cells produced in the bone marrow. This timeline gives the bone marrow plenty of time to manufacture replacement cells at a steady pace, maintaining a healthy balance^[1][5]. In cold agglutinin disease, this orderly process breaks down. Red blood cells are destroyed much faster than normal – sometimes surviving only a few days – while the bone marrow struggles to keep up with the accelerated demand for replacement cells^[1].

The destruction process begins with the production of abnormal autoantibodies, typically IgM molecules. These antibodies have an unusual property: they bind most effectively to red blood cells when temperatures drop below normal body temperature. In approximately 90% of cases, the culprit is a monoclonal IgM autoantibody, meaning it comes from a single clone of abnormal immune cells^[3][4]. Less commonly, the autoantibody may be polyclonal (from multiple cell lines) or involve different antibody types like IgG, IgA, or light chains.

The thermal range at which these autoantibodies become active is critical to understanding the disease. The process typically begins when body parts cool to approximately 37 to 39 degrees Fahrenheit (3 to 4 degrees Celsius)^[1][8]. This commonly occurs in parts of the body that are farther from the warm core, such as the fingers, toes, ears, and nose. As blood circulates through these cooler areas, the cold-reactive autoantibodies attach themselves to the surface of red blood cells.

Once coated with IgM antibodies, red blood cells undergo agglutination – they clump together into visible aggregates. This clumping can sometimes be observed under a microscope when examining blood samples^[3]. The clumped cells are much easier targets for destruction than individual cells would be. More importantly, the antibody-coated cells activate the complement system, a cascade of proteins that form part of the immune system’s defence mechanism.

The complement pathway proceeds through several steps, with complement proteins attaching to the antibody-marked red blood cells. The most important of these is complement component C3, which breaks down into C3d and remains attached to the red blood cell surface even after the cell warms back up and the IgM antibody may have detached^[3][4]. This persistent C3d marking is why diagnostic tests often show positive results for C3 on the red blood cell surface.

The actual destruction of red blood cells happens through two main mechanisms. Some cells undergo intravascular haemolysis, meaning they break apart while still circulating in the bloodstream^[4]. This releases haemoglobin directly into the blood plasma, which can then appear in the urine, causing it to turn dark. More commonly, complement-coated red blood cells are removed through extravascular haemolysis. In this process, macrophages – large immune cells stationed primarily in the spleen and liver – recognize and consume the marked red blood cells, removing them from circulation.

The breakdown of red blood cells, regardless of mechanism, releases haemoglobin. This haemoglobin is then broken down into components including bilirubin, a yellow pigment. When bilirubin accumulates faster than the liver can process and excrete it, it builds up in the blood and tissues, causing the yellow discolouration of jaundice seen in many patients^[1][5].

The severity of disease and symptoms depends heavily on several factors. The thermal amplitude – meaning the temperature range at which the autoantibody remains active – plays a crucial role^[4]. Autoantibodies that remain active at higher temperatures (closer to normal body temperature) cause more severe disease because red blood cells can be attacked in more areas of the body, not just the coolest extremities. The titre or concentration of the autoantibody also matters, with higher titres typically causing more severe haemolysis.

In primary cold agglutinin disease, the underlying pathology often involves a clonal B-cell disorder in the bone marrow. These abnormal B-cell clones produce the pathogenic IgM antibodies^[4]. While this is not typically classified as cancer, it represents an abnormal proliferation of immune cells that can sometimes progress to lymphoma. The bone marrow in affected individuals may show characteristic features including nodular collections of B-cells and lymphoplasmacytoid cells^[4].

In secondary cold agglutinin disease triggered by infections, the mechanism differs somewhat. Certain infections, particularly Mycoplasma pneumoniae and Epstein-Barr virus, can stimulate the immune system to produce cold-reactive autoantibodies^[2][4]. In these cases, the autoantibodies are often polyclonal (from multiple cell lines) rather than monoclonal, and the condition usually resolves once the infection is cleared and the abnormal immune stimulation subsides.

The body attempts to compensate for the accelerated red blood cell destruction by ramping up production in the bone marrow. This increased activity is reflected in elevated reticulocyte counts – reticulocytes are immature red blood cells released early from the bone marrow in response to anaemia. However, if destruction outpaces production, or if the bone marrow cannot respond adequately, significant anaemia develops, leading to the clinical symptoms patients experience.